Difunctional cavings oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity
By chemically synthesizing the gluten bran oligopeptide GK-8, we have addressed the lack of research on the prevention and treatment of metabolic syndrome and the enhancement of immunity by gluten bran protein peptides. This study has achieved significant results in reducing metabolic syndrome indicators and enhancing immune function in mice, and it exhibits good stability and selective PPARγ regulatory capacity.
Patent Information
- Application Number
- CN202411247054.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-29
AI Technical Summary
There is a relative lack of reports on the active ingredients of gluten protein peptides in the current technology, and there is a lack of bioactive peptides with drug development potential, especially in the prevention and treatment of metabolic syndrome and the enhancement of immunity.
The amino acid sequence of gluten bran oligopeptide GK-8 was determined to be Gly-Leu-Ser-Phe-Asp-Phe-Tyr-Lys (GLSFDFYK). Through mouse model experiments, it was found that it has significant dual effects in preventing and treating metabolic syndrome and improving immunity. Its chemical synthesis and non-toxicity and potential sensitization were verified. As a selective PPARγ regulator, it binds to PPARγ and weakly activates it, and can be applied to the development of health products and pharmaceuticals.
Glutamic acid oligopeptide GK-8 significantly reduces metabolic syndrome-related indicators in mice, improves steatosis, enhances immune function, and regulates PPARγ nuclear translocation. It has good stability and bioavailability and is suitable for dual-function applications in the prevention and treatment of metabolic syndrome and the enhancement of immunity.
Smart Images

Figure CN119039387A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of bioactive peptides, and specifically relates to a dual-functional grain bran oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity and an application thereof. Background Art
[0002] Plant small molecule peptide compounds are a class of active factors that are beneficial to human health. The order of amino acids that make up the bioactive peptides determines their different physiological activities. Compared with proteins, these small molecule peptides have clear molecular structures, better digestion and absorption capabilities, and better stability, making them an important resource for the research and development of natural drugs. At present, antimicrobial peptides, antioxidant peptides, antihypertensive peptides, immunomodulatory peptides, hypoglycemic peptides, and anti-tumor peptides have been separated and purified from plants, and have broad market application prospects in the medical field.
[0003] Millet is a major grain crop in my country, and its byproduct, bran, is rich in a large number of high-quality protein peptides. Studies have shown that bran protein is the lowest allergenic protein among known cereals, and its protein digestibility and essential amino acid composition are significantly better than millet, with high nutritional value and great medical research value. However, there is a relative lack of reports on the effective components of bran protein peptides, and only a small number of studies have been conducted. For example, it has been found that bran enzymatic peptides can significantly inhibit liver damage and precancerous diseases caused by aminopyrine-sodium nitrite; they can regulate NF-kB and MAPK signaling pathways, reduce LPS-induced inflammatory responses in mice, and resist hypertension. Therefore, it is of great significance to explore small molecule bioactive peptides with potential for drug development from bran protein peptides. Summary of the invention
[0004] In view of the above problems, the object of the present invention is to provide a dual-functional bran oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity and its application.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] First, the amino acid sequence and physicochemical properties of the bran oligopeptide GK-8 were determined and chemically synthesized; then, through mouse model experiments, it was found that the oligopeptide has the dual effects of significantly preventing and treating metabolic syndrome and improving immunity; at the same time, it was found that it can bind to and activate PPARγ as a selective PPARγ modulator. The bran oligopeptide GK-8 provided by the present invention is expected to be further developed into a new type of health product and / or medicine.
[0007] Specifically:
[0008] In the first aspect, the present invention provides a dual-functional bran oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity and its application, wherein the amino acid sequence of the oligopeptide is Gly-Leu-Ser-Phe-Asp-Phe-Tyr-Lys (GLSFDFYK, referred to as GK-8), and its chemical structure is as follows Figure 1 .
[0009] Furthermore, Aller TOP v.2.0 software and Toxin Pred software were used to predict the toxicity and potential allergenicity of GK-8, and the results showed that the grain bran oligopeptide GK-8 had no toxicity and potential allergenicity.
[0010] Furthermore, the bran oligopeptide GK-8 can be obtained by artificial synthesis (see Example 2), and its purity is ≥98%. Its stability is evaluated by circular dichroism, and it is found that GK-8 has good stability at different temperatures and different pH values.
[0011] In the second aspect, the present invention provides an application of a bifunctional bran oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity. The bran oligopeptide GK-8 can significantly reduce the metabolic syndrome-related indicators of mice in the prevention group and treatment group models induced by a high-fat diet, which are specifically manifested as follows: GK-8 can significantly reduce the body weight of mice and improve fatty degeneration; by lowering the blood sugar of mice and increasing the glucose uptake in the body of mice, the insulin resistance effect is significantly alleviated; the levels of triglycerides TG, total cholesterol TC, and low-density lipoprotein LDL-C in the serum of mice are significantly reduced, and the level of high-density lipoprotein HDL is significantly increased.
[0012] Furthermore, the bran oligopeptide GK-8 can significantly regulate the immune activity of cyclophosphamide-induced immunosuppressed mice. Specifically, the bran oligopeptide GK-8 can significantly increase the body weight, thymus index and spleen index of immunosuppressed mice, and enhance the proliferation capacity of mouse spleen T lymphocytes and B lymphocytes and the killing activity of NK cells.
[0013] In a third aspect, the present invention provides an application of a dual-functional bran oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity, wherein the bran oligopeptide GK-8 is a selective PPARγ regulator.
[0014] Furthermore, the bran oligopeptide GK-8 can interact with PPARγ, weakly activate PPARγ to cause nuclear translocation, play a role in enhancing insulin sensitization and preventing and treating metabolic syndrome, and has no obvious adverse reactions to the body. It is a selective PPARγ regulator with good effects.
[0015] In a fourth aspect, the present invention provides a health product and / or medicine for preventing and treating metabolic syndrome and improving immunity, comprising the above-mentioned grain bran oligopeptide GK-8.
[0016] Compared with the prior art, the bran oligopeptide GK-8 provided by the present invention has the following advantages: no toxicity and potential allergenicity; small molecular weight, easy to be absorbed by the body; good stability; dual efficacy of preventing and treating metabolic syndrome and improving immune regulation ability, and can be used as a selective PPARγ modulator with considerable development prospects. In summary, the bran oligopeptide GK-8 has good biological activity and high bioavailability, and has considerable application potential and broad market application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0018] Figure 1 : GK-8 chemical structure;
[0019] Figure 2 : GK-8 has good stability;
[0020] Figure 3 : Experimental procedures of metabolic syndrome prevention group;
[0021] Figure 4 :GK-8 significantly reduced the body weight and abdominal fat content of the metabolic syndrome prevention group mouse model induced by a high-fat diet;
[0022] Figure 5 :GK-8 significantly improves insulin resistance in the high-fat diet-induced metabolic syndrome prevention group mouse model;
[0023] Figure 6 :GK-8 significantly improved the serum lipid content of the high-fat diet-induced metabolic syndrome prevention group mouse model;
[0024] Figure 7 : Experimental procedures of metabolic syndrome treatment group;
[0025] Figure 8 :GK-8 significantly reduced the body weight and abdominal fat content of the high-fat diet-induced metabolic syndrome mouse model;
[0026] Fig. 9 :GK-8 significantly improved insulin resistance in the high-fat diet-induced metabolic syndrome treatment group mouse model;
[0027] Fig.10:GK-8 significantly improved the serum lipid content of the high-fat diet-induced metabolic syndrome treatment group mouse model;
[0028] Fig.11 :GK-8 significantly increased the body weight, thymus index and spleen index of immunosuppressive mouse model;
[0029] Fig.12 :GK-8 significantly enhanced the proliferation of T lymphocytes and B lymphocytes in the spleen of mice and the killing activity of NK cells;
[0030] Fig.13 : GK-8 interacts with and weakly activates PPARγ. DETAILED DESCRIPTION
[0031] In order to make the purpose, technical solution and advantages of the present invention more clear, the present invention is further described in detail in combination with specific embodiments. The specific embodiments described here are only used to explain the present invention and are not used to limit the present invention.
[0032] All experimental results in the following examples are expressed as mean ± standard deviation (Mean ± SD), and the differences between the groups were compared by one-way analysis of variance (ANOVA), and the "Duncan" test was selected for significance analysis. * indicates that there is a significant difference between the blank group and each group (p < 0.05), and ** indicates that there is an extremely significant difference between the blank group and each group (p < 0.01).
[0033] Example 1: Evaluation of the toxicity and potential allergenicity of GK-8
[0034] The structure of GK-8 was drawn using Chem Draw Professional 20.0 software. Figure 1 As shown. AllerTOP v.2.0 software and Toxin Pred software were used to predict the toxicity and potential allergenicity of GK-8. Aller TOP v.2.0 software is based on the description of the hydrophobicity, size, abundance, and helix and folding formation tendencies of amino acid residues of proteins and polypeptides. It uses the K nearest neighbor algorithm to classify 2427 known allergenic proteins and 2427 non-allergenic proteins, and predicts their potential allergenicity by matching target peptides. Toxin Pred software can predict the safety of target peptides by matching them with known peptides in the database based on the specific amino acid characteristics of the target peptides. The prediction results are shown in Table 1. GK-8 has no toxicity and potential allergenicity.
[0035] Table 1 Non-toxicity and potential allergenicity of grain bran oligopeptide GK-8
[0036]
[0037] Example 2: Chemical synthesis, purity and stability of GK-8
[0038] The solid phase peptide synthesis (SPPS) method was used to synthesize the bran oligopeptide GK-8 (GLSFDFYK), and the purity of the synthesized oligopeptide was ≥98%. SPPS is to couple amino acids to the resin in sequence to form a peptide chain. After the sequence synthesis is completed, the N-terminal Fmoc protecting group is first deprotected, and after the N-terminal modification is completed, the side chain protecting group is deprotected and the peptide is cleaved from the resin. The main process includes the following points:
[0039] 1. Resin treatment: Take an appropriate amount of modified resin, add the prepared amino acid solution into the resin, and react;
[0040] 2. Remove Fmoc: Add Pip / DMF solution and remove the solvent by vacuum filtration;
[0041] 3. Washing: Add DMF4 solution to the resin and remove the solvent by vacuum filtration;
[0042] 4. Resin detection: Put the detection reagents A, B and resin into a test tube, then put the test tube into hot water for a few seconds to check whether the color of the resin changes. If the color of the resin changes, the Fmoc group is successfully removed;
[0043] 5. Amino acid condensation: Add the prepared amino acid solution to the resin, then add the coupling reagent, shake well, and remove the solvent by vacuum filtration;
[0044] 6. Repeat steps 2-5 until the last amino acid is synthesized.
[0045] Circular dichroism spectroscopy can reveal the conformational changes of proteins by measuring their circular dichroism spectra under different conditions, thereby evaluating the stability of proteins and changes in their folding states. The stability of GK-8 can be explored by scanning the circular dichroism spectra of GK-8 at different temperatures and different pH values. The results are as follows Figure 2 As shown in the figure, GK-8 has good stability under different temperatures and pH conditions.
[0046] Example 3: In vivo evaluation of the efficacy of grain bran oligopeptide GK-8 in preventing metabolic syndrome
[0047] 1. Animal source: C57BL / 6J male mice; 4 weeks old, 15-18g
[0048] 2. Feeding conditions and feed: Ordinary level, environmental temperature conditions are 26±1℃, humidity conditions are 60±5%, indoor lighting simulates day and night, 12-hour light and dark cycle. All mice except the control group were fed with high-fat diet (HFD), and the control group was fed with ordinary maintenance feed for 12 weeks. The GK-8 administration group was gavaged with different doses every day, and the control group and the model group were gavaged with the same volume of normal saline until the end of the experiment.
[0049] 3. Experimental animal groups (Table 2):
[0050] Table 2 Grouping of experimental animals in the metabolic syndrome prevention group
[0051]
[0052] 4. Experimental Procedure Figure 3 )
[0053] 5. Detection of serum biochemical indices of mice. One week before the mice were killed, the tails were cut off and blood was collected after fasting for 12 hours. 20% glucose in normal saline was given by gavage at a dose of 2g / kg. Blood glucose levels were measured at 0, 0.25, 0.5, 1 and 2 hours using a blood glucose meter to conduct a glucose tolerance test. Four days later, after fasting for 2 hours, recombinant human insulin was intraperitoneally injected at a dose of 0.75U / kg. Blood glucose levels were measured at 0, 0.25, 0.5, 1 and 2 hours to conduct an insulin tolerance test. The levels of TG, TC, LDL-C and HDL-C in mouse serum were determined using a full-wavelength multifunctional microplate reader.
[0054] H&E staining was used to detect pathological indicators. After 12 weeks, the mice were anesthetized in ether and killed by cervical dislocation. The mice were dissected, and the epididymal white adipose tissue and brown adipose tissue were removed and fixed in 4% paraformaldehyde. After 24 hours, they were embedded in paraffin and sectioned. H&E staining was then performed, and the tissue was observed under an optical microscope after sealing with a dehydrated sealing medium.
[0055] 6. Experimental Results
[0056] (1) GK-8 improves body weight and abdominal fat content in the metabolic syndrome prevention group animal model
[0057] Depend on Figure 4 It can be seen that compared with the mice in the M group, the weight gain of the GK-8 group was inhibited ( Figure 4 A); Compared with the M group, the average total weight of epididymal fat in the GK-8 group was lower ( Figure 4 B), and H&E staining clearly showed that the epididymal adipose tissue adipocytes were less swollen and the brown adipose tissue was denser after administration ( Figure 4C). These results all indicate that GK-8 can effectively improve the body weight and abdominal fat content of the metabolic syndrome prevention group model mice.
[0058] (2) GK-8 improves insulin resistance in the metabolic syndrome prevention group animal model
[0059] Depend on Figure 5 It can be seen that the fasting blood glucose level of mice in the M group was significantly higher than that of mice in the GK-8 group at 12 weeks ( Figure 5 A); After GK-8 administration, both oral glucose tolerance test and insulin tolerance test showed positive improvement ( Figure 5 BE). The above experimental results suggest that grain bran oligopeptide GK-8 can improve insulin resistance and alleviate metabolic syndrome.
[0060] (3) GK-8 improves serum lipid levels in the metabolic syndrome prevention group animal model
[0061] The International Diabetes Federation defines metabolic syndrome as the presence of central obesity and two or more of the following conditions: elevated triglyceride (TG) levels or drug treatment for hypertriglyceridemia; decreased high-density lipoprotein cholesterol (HDL-C) levels or drug treatment for hypoHDL-C; elevated fasting blood glucose (FBG) or diagnosed diabetes; elevated blood pressure (systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg) or drug treatment for hypertension. To further verify the effect of GK-8 on lipid metabolism, the levels of serum triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL-C), and high-density lipoprotein (HDL-C) were detected. Figure 6 It can be seen that compared with the M group, the GK-8 group reduced the blood lipid levels of mice with metabolic syndrome induced by a high-fat diet, indicating that the bran oligopeptide GK-8 can alleviate metabolic syndrome by inhibiting lipid circulation.
[0062] Example 4: In vivo evaluation of the efficacy of GK-8 in treating metabolic syndrome
[0063] 1. Animal source: C57BL / 6J male mice; 4 weeks old, 15-18g
[0064] 2. Feeding conditions and feed: Ordinary level, environmental temperature conditions are 26±1℃, humidity conditions are 60±5%, indoor lighting simulates day and night, and 12-hour light and dark cycle. All mice except the control group were fed with high-fat feed, and the control group was fed with ordinary maintenance feed for 12 weeks. The model group was identified 6 weeks after modeling. After the model was successfully identified, the drug group was given GK-8 by gavage. Mice were gavaged with different doses every day, and the control group and the model group were gavaged with the same volume of saline until the end of the experiment.
[0065] 3. Experimental animal groups (Table 3):
[0066] Table 3 Grouping of experimental animals in the metabolic syndrome treatment group
[0067]
[0068] 4. Experimental Procedure Figure 7 )
[0069] 5. Detection of serum biochemical indices of mice. One week before the mice were killed, the tails were cut off and blood was collected after fasting for 12 hours. 20% glucose in normal saline was given by gavage at a dose of 2g / kg. Blood glucose levels were measured at 0, 0.25, 0.5, 1 and 2 hours using a blood glucose meter to conduct a glucose tolerance test. Four days later, after fasting for 2 hours, recombinant human insulin was intraperitoneally injected at a dose of 0.75U / kg. Blood glucose levels were measured at 0, 0.25, 0.5, 1 and 2 hours to conduct an insulin tolerance test. The levels of TG, TC, LDL-C and HDL-C in mouse serum were determined using a full-wavelength multifunctional microplate reader.
[0070] H&E staining was used to detect pathological indicators. After 12 weeks, the mice were anesthetized in ether and killed by cervical dislocation. The mice were dissected, and the epididymal white adipose tissue and brown adipose tissue were removed and fixed in 4% paraformaldehyde. After 24 hours, they were embedded in paraffin and sectioned. H&E staining was then performed, and the tissue was observed under an optical microscope after sealing with a dehydrated sealing medium.
[0071] 6. Experimental Results
[0072] (1) GK-8 improves body weight and abdominal fat content in metabolic syndrome treatment group animal models
[0073] Depend on Figure 8 It can be seen that compared with the mice in the M group, the weight gain of the GK-8 group was inhibited ( Figure 8 A); Compared with the M group, the average total weight of epididymal fat in the GK-8 group was lower ( Figure 8 B), and H&E staining clearly showed that the epididymal adipose tissue adipocytes were less swollen and the brown adipose tissue was denser after administration ( Figure 8 C). These results all indicate that GK-8 can effectively improve the body weight and abdominal fat content of the metabolic syndrome treatment group model mice.
[0074] (2) GK-8 improves insulin resistance in metabolic syndrome treatment animal models
[0075] Depend on Fig. 9 It can be seen that the fasting blood glucose level of mice in the M group was significantly higher than that of mice in the GK-8 group at 12 weeks ( Fig. 9 A); After GK-8 administration, both oral glucose tolerance test and insulin tolerance test showed positive improvement ( Fig. 9 BE). The above experimental results suggest that grain bran oligopeptide GK-8 can improve insulin resistance and alleviate metabolic syndrome.
[0076] (3) GK-8 improved serum lipid levels in the metabolic syndrome treatment group animal model
[0077] In order to further verify the effect of grain bran oligopeptide GK-8 on lipid metabolism, the levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL-C), and high-density lipoprotein (HDL-C) in serum were detected. Fig.10 It can be seen that compared with the M group, the GK-8 group reduced the blood lipid levels of mice with metabolic syndrome induced by a high-fat diet, indicating that the bran oligopeptide GK-8 can alleviate metabolic syndrome by inhibiting lipid circulation.
[0078] Example 5: In vivo evaluation of the efficacy of oligopeptide GK-8 in improving immunity
[0079] 1. Animal source: BALB / c male mice; 6 weeks old, 18-22g
[0080] 2. Feeding conditions and feed: Ordinary level, environmental temperature conditions are 22±2℃, humidity conditions are 60±5%, indoor lighting simulates day and night, and 12-hour light and dark cycle. After the mice adapted to the environment for 7 days (d), except for the control group, the other groups of mice were intraperitoneally injected with cyclophosphamide for 3 consecutive days to establish an immunosuppressive mouse model; the control group and the model group were given normal saline every day, the drug-treated group was given GK-8 every day, and the positive control group was given levamisole hydrochloride; after continuous gavage for 19 days according to the dosage of each group, the mice were killed by cervical dislocation, and the internal organs, blood and intestinal contents were collected for subsequent experiments. The experimental animals were grouped as follows:
[0081] Table 4 Grouping of animals in immunization experiments
[0082]
[0083] 3. Experimental results
[0084] (1) GK-8 significantly increased the body weight and spleen and thymus indexes of immunosuppressive mouse models
[0085] like Fig.11 As shown in the figure, during the adaptive feeding stage, the weight of mice increased; after the model was established, the weight of mice treated with Cy decreased, while the weight of mice in group C continued to increase; the weight of mice in group GK-8 and group PC gradually increased. Among them, the weight of group M was significantly lower than that of group C, and the difference between the two groups was significant. The weight of the PC group and the GK-8 group recovered well, and the weight of the GK-8 group almost recovered to the level of group C ( Fig.11 A).
[0086] The thymus and spleen are important components of the immune system, and the immune stimulation activity is closely related to the changes in the thymus index and spleen index. Fig.11 It can be seen that compared with group C, the thymus index of group M was significantly reduced, indicating that the cyclophosphamide-induced immunosuppressive mouse model was successful. Under the action of the immunosuppressant Cy, the spleen of group M was enlarged. Compared with group M, the thymus index of mice in group GK-8 was significantly increased, indicating that GK-8 has a significant inhibitory effect on mouse spleen enlargement ( Fig.11 B, C).
[0087] (2) GK-8 significantly enhanced the proliferation of T lymphocytes and B lymphocytes in the spleen of mice and the killing activity of NK cells
[0088] The proliferation and differentiation of lymphocytes play a key role in the body's immune response. Both T and B lymphocytes have receptors that can recognize antigens and mitotic receptors on their surfaces. These receptors promote the proliferation of corresponding lymphocytes under the stimulation of specific antigens. Fig.12 As shown in the figure, compared with the C group, the proliferation capacity of T lymphocytes in the M group mice was significantly reduced. Compared with the M group, the proliferation capacity of T lymphocytes in the GK-8 group mice was significantly increased ( Fig.12 A), compared with group C, the proliferation capacity of B lymphocytes in group M mice was significantly reduced. Compared with group M, the proliferation capacity of B lymphocytes in group GK-8 mice was significantly increased ( Fig.12 B). The experimental results showed that intraperitoneal injection of Cy decreased the proliferation and differentiation ability of lymphocytes in mice, while GK-8 restored the proliferation ability of lymphocytes in immunosuppressed mice, and compared with LH, GK-8 showed better proliferation ability on lymphocytes.
[0089] NK cells are another important immune cell in the body besides T and B lymphocytes. They are another important indicator of the body's immune function. Fig.12 It can be seen that compared with the C group, the killing activity of NK cells in the M group mice was significantly reduced. Compared with the M group, the killing activity of NK cells in the GK-8 group mice was significantly improved ( Fig.12 C) GK-8 treatment restored the NK cell cytotoxicity of Cy-induced immunosuppressed mice to a large extent.
[0090] Example 6: Verification of the interaction between GK-8 and PPARγ in vitro and in vivo
[0091] The Gator Bio molecular interaction system was used to evaluate the binding ability of PPARγ and GK-8, and to detect the affinity and related kinetic parameters of the two. Fig.13 As shown, PPARγ can interact with GK-8 with a KD value of 3.49E-006 ( Fig.13A). Western blot results showed that after GK-8 treatment, there was no significant difference in the expression of PPARγ in the cytoplasm among the groups, while the expression of PPARγ in the nucleus was significantly higher than that in the model group ( Fig.13 B, C). The statistical analysis of the nuclear-cytoplasmic ratio of PPARγ in each group revealed that GK-8 could significantly induce the nuclear translocation of PPARγ, thereby activating PPARγ ( Fig.13 D); Dual luciferase reporter gene system showed that after treatment with different concentrations of GK-8, PPARγ was activated to a certain extent (Table 5). The above results indicate that GK-8 interacts with PPARγ and can weakly activate PPARγ and promote its nuclear translocation.
[0092] Table 5 Dual luciferase reporter gene system to detect the activation effect of GK-8 on PPARγ
[0093]
[0094] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of protection of the invention. It should be pointed out that, for a person of ordinary skill in the art, the above-mentioned implementation methods can also be modified, combined and improved without departing from the concept of the present invention, and these all belong to the protection scope of this patent. Therefore, the protection scope of this patent shall be subject to the claims.
Claims
1. A dual-functional bran oligopeptide GK-8 for preventing and treating metabolic syndrome and improving immunity, characterized in that: The amino acid sequence of the oligopeptide is Gly-Leu-Ser-Phe-Asp-Phe-Tyr-Lys.
2. Use of the bran oligopeptide GK-8 as claimed in claim 1 in the preparation of drugs for preventing and treating metabolic syndrome and improving immunity.
3. Use of the bran oligopeptide GK-8 as claimed in claim 1 in the preparation of a medicament for preventing and treating metabolic syndrome.
4. Use of the bran oligopeptide GK-8 as claimed in claim 1 in the preparation of a drug for improving immunity.
5. Use of the bran oligopeptide GK-8 as claimed in claim 1 in the preparation of a selective PPARγ modulator drug.
6. A health product and / or medicine for preventing and treating metabolic syndrome and improving immunity, characterized in that: Contains the bran oligopeptide GK-8 as claimed in claim 1.
Citation Information
Patent Citations
Bran coat active peptide capable of relieving metabolic syndrome as well as preparation method and application of bran coat active peptide
CN115785219A
Cited By
Bran coat polypeptide GR-12 with immunoregulation function and application of bran coat polypeptide GR-12
CN119823230A
Nonapeptide with immunomodulatory effect as well as preparation and application of nonapeptide
CN119874827A
A nonapeptide with immunomodulatory effects, its preparation and application
CN119874827B
Hydrogel loaded with cavings oligopeptide GK-8 as well as preparation method and application of hydrogel
CN122139808A
